Radiprodil pediatric formulation development
Radiprodil is currently under development for the treatment of Infantile Spasm (IS), a rare and catastrophic seizure disorder that occurs in young children. In this perspective, a suitable formulation purposely designed for the treatment of the target paediatric population infants from 2 to 14 months was developed taking into account the ideal attributes of a paediatric formulation (i.e. to grant flexible dosage increments in an accurate way; to allow compliance; to be palatable; safe and easy to administer; with minimum excipients and stable). The key challenges faced during development are herein presented and discussed.
Recently presented by our expert, Emanuela Del Vesco, in collaboration with UCB, at the 11th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, get your copy of our educational scientific poster and discover more!